EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Strategy to Improve the Oral Pharmacokinetics of Cyclin-Dependent Kinase 4/6 Inhibitors: Enhancing Permeability and CYP450 Inhibition by a Natural Bioenhancer

Prajakta Harish Patil, Mrunal Pradeep Desai, Rajat Radhakrishna Rao, Srinivas Mutalik, Jagadish Puralae Channabasavaiah

AAPS PharmSciTech · 2024

DOI: 10.1208/s12249-024-02899-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AAPS PharmSciTech, 2024. Verfasst von Prajakta Harish Patil und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, …. Hauptthemen laut MEDLINE: Biological Availability, Cyclin-Dependent Kinase 6, Flavanones, Protein Kinase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Manipal Academy of Higher Education, Manipal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Palbociclib and ribociclib an orally bioavailable, potent cyclin-dependent kinase 4/6 inhibitors, with low oral bioavailability due to substrate specificity towards CYP3A and P-glycoprotein. Thus, current research aims to examine the effect of a bioenhancer (naringin), on oral pharmacokinetics of palbociclib and ribociclib. Naringin’s affinity for CYP3A4 and P-glycoprotein was studied using molecular docking; its impact on palbociclib/ribociclib CYP3A metabolism and P-glycoprotein-mediated efflux was examined using in vitro preclinical models; and its oral pharmacokinetics in rats were assessed following oral administration of palbociclib/ribociclib in presence of naringin (50 and 100 mg/kg). Naringin binds optimally to both proteins with the highest net binding energy of − 1477.23 and − 1607.47 kcal/mol, respectively. The microsomal intrinsic clearance of palbociclib and ribociclib was noticeably reduced by naringin (5–100 µM), by 3.0 and 2.46-folds, respectively. Similarly, naringin had considerable impact on the intestinal transport and efflux of both drugs. The pre-treatment with 100 mg/kg naringin increased significantly ( p < 0.05) the oral exposure of palbociclib (2.0-fold) and ribociclib (1.95-fold). Naringin's concurrent administration of palbociclib and ribociclib increased their oral bioavailability due to its dual inhibitory effect on CYP3A4 and P-glycoprotein; thus, concurrent naringin administration may represent an innovative strategy for enhancing bioavailability of cyclin-dependent kinase inhibitors. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological AvailabilityCyclin-Dependent Kinase 6FlavanonesProtein Kinase InhibitorsAnimalsHumansRatsAdministration, OralAminopyridinesATP Binding Cassette Transporter, Subfamily B, Member 1BioenhancersCaco-2 CellsCyclin-Dependent Kinase 4Cytochrome P-450 CYP3ACytochrome P-450 Enzyme InhibitorsMolecular Docking SimulationPermeabilityPiperazinesPurinesPyridinesRats, Sprague-Dawley

Stichwörter der Autor:innen

CDK4/6 inhibitorsbio-enhancerbioavailabilitydietary flavonoidsnaringinpharmacokinetics

Substanzen

AminopyridinesATP Binding Cassette Transporter, Subfamily B, Member 1BioenhancersCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Cytochrome P-450 CYP3ACytochrome P-450 Enzyme InhibitorsFlavanonesnaringinpalbociclib

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India.
  • Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India.
  • Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India. jagadish.pc@manipal.edu.

Förderung

  • Manipal Academy of Higher Education, Manipal

Zitieren

APA

Patil, P. H., Desai, M. P., Rao, R. R., Mutalik, S., & Puralae Channabasavaiah, J. (2024). Strategy to Improve the Oral Pharmacokinetics of Cyclin-Dependent Kinase 4/6 Inhibitors: Enhancing Permeability and CYP450 Inhibition by a Natural Bioenhancer. AAPS PharmSciTech. https://doi.org/10.1208/s12249-024-02899-3

Vancouver

Patil PH, Desai MP, Rao RR, Mutalik S, Puralae Channabasavaiah J. Strategy to Improve the Oral Pharmacokinetics of Cyclin-Dependent Kinase 4/6 Inhibitors: Enhancing Permeability and CYP450 Inhibition by a Natural Bioenhancer. AAPS PharmSciTech. 2024. doi:10.1208/s12249-024-02899-3

BibTeX
@article{Patil2024,
  author = {Patil, Prajakta Harish and Desai, Mrunal Pradeep and Rao, Rajat Radhakrishna and Mutalik, Srinivas and Puralae Channabasavaiah, Jagadish},
  title = {Strategy to Improve the Oral Pharmacokinetics of Cyclin-Dependent Kinase 4/6 Inhibitors: Enhancing Permeability and CYP450 Inhibition by a Natural Bioenhancer},
  journal = {AAPS PharmSciTech},
  year = {2024},
  doi = {10.1208/s12249-024-02899-3}
}
Kostenlos starten →